Investigational drug · Phase 3
ADX-2191
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Primary Vitreoretinal Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ADX-2191"
First trial start
2027
Dec 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ADX-2191", any sponsor or status.
Conditions studied
As listed on its trial records.
- Primary Vitreoretinal Lymphoma
Approved drugs for the same conditions: Hematology and blood cancers · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "ADX-2191" as an intervention, largest first.
- The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative VitreoretinopathyPivotal-lookingCompleted
Aldeyra Therapeutics, Inc.Industry
NCT04136366 · 106 participants · Start Nov 15, 2019 · Primary completion Jun 14, 2022
Drug: ADX-2191 (intravitreal methotrexate 0.8%) · For: Proliferative Vitreoretinopathy
Sites: Phoenix, Arizona; Los Angeles, California; Orlando, Florida · 23 sites in all
- A Clinical Trial Evaluating Patients With Primary Vitreoretinal LymphomaPivotal-lookingRecruiting
Aldeyra Therapeutics, Inc.Industry
NCT07402876 · 20 participants (planned) · Start Dec 2027 · Primary completion Dec 2029
Drug: ICM ADX-2191 injection; Monthly ADX-2191 injection · For: Primary Vitreoretinal Lymphoma
Sites: Miami, Florida
Aldeyra Therapeutics, Inc.Industry
NCT05392179 · 8 participants · Start Jul 14, 2022 · Primary completion Jun 23, 2023
Drug: ADX-2191; ADX-2191 · For: Retinitis Pigmentosa
Sites: Durham, North Carolina
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.